BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 21478269)

  • 1. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
    Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
    Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chaperone-dependent stabilization and degradation of p53 mutants.
    Muller P; Hrstka R; Coomber D; Lane DP; Vojtesek B
    Oncogene; 2008 May; 27(24):3371-83. PubMed ID: 18223694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
    Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
    Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization.
    Peng Y; Chen L; Li C; Lu W; Chen J
    J Biol Chem; 2001 Nov; 276(44):40583-90. PubMed ID: 11507088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
    Xu C; Fan CD; Wang X
    Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
    Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
    Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AQP2 Abundance is Regulated by the E3-Ligase CHIP Via HSP70.
    Centrone M; Ranieri M; Di Mise A; Berlingerio SP; Russo A; Deen PMT; Staub O; Valenti G; Tamma G
    Cell Physiol Biochem; 2017; 44(2):515-531. PubMed ID: 29145196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
    Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
    J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ubiquitination and degradation of mutant p53.
    Lukashchuk N; Vousden KH
    Mol Cell Biol; 2007 Dec; 27(23):8284-95. PubMed ID: 17908790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ErbB2 degradation mediated by the co-chaperone protein CHIP.
    Zhou P; Fernandes N; Dodge IL; Reddi AL; Rao N; Safran H; DiPetrillo TA; Wazer DE; Band V; Band H
    J Biol Chem; 2003 Apr; 278(16):13829-37. PubMed ID: 12574167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2.
    Wiech M; Olszewski MB; Tracz-Gaszewska Z; Wawrzynow B; Zylicz M; Zylicz A
    PLoS One; 2012; 7(12):e51426. PubMed ID: 23251530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation.
    Sasaki M; Nie L; Maki CG
    J Biol Chem; 2007 May; 282(19):14626-34. PubMed ID: 17363365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
    Yang L; Song T; Cheng Q; Chen L; Chen J
    Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent.
    Whitesell L; Sutphin PD; Pulcini EJ; Martinez JD; Cook PH
    Mol Cell Biol; 1998 Mar; 18(3):1517-24. PubMed ID: 9488468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buxus alkaloid compound destabilizes mutant p53 through inhibition of the HSF1 chaperone axis.
    Wang YL; Wu W; Su YN; Ai ZP; Mou HC; Wan LS; Luo Y; Qiu MH; Zhang JH
    Phytomedicine; 2020 Mar; 68():153187. PubMed ID: 32097779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
    Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
    J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ca2+/S100 proteins act as upstream regulators of the chaperone-associated ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein).
    Shimamoto S; Kubota Y; Yamaguchi F; Tokumitsu H; Kobayashi R
    J Biol Chem; 2013 Mar; 288(10):7158-68. PubMed ID: 23344957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer.
    Ruckova E; Muller P; Nenutil R; Vojtesek B
    Cell Mol Biol Lett; 2012 Sep; 17(3):446-58. PubMed ID: 22669480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 chaperones the p53 tumor suppressor.
    Wawrzynow B; Zylicz A; Wallace M; Hupp T; Zylicz M
    J Biol Chem; 2007 Nov; 282(45):32603-12. PubMed ID: 17848574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.